clioquinol (5-chloro-7-iodo-8-hydroxyquinoline)
Jump to navigation
Jump to search
Indications
- once used as anti-amoebic agent
Adverse effects
- subacute myelo-optico-neuropathy [SMON] (most likely subacute combined degeneration) probably related to vitamin B12 deficiency
Mechanism of action
- halogenated 8-hydroxyquinoline[1]
- chelates metal ions, binds Zn+2 & Cu+2 with greater affinity than Ca+2 & Mg+2
- lipophilic, freely crosses blood brain barrier
Clinical trials
- never emerged from phase II clinical trial for Alzheimer's disease 3/02
More general terms
- quinoline; leucoline; chinoleine; 1-benazazine; benzo[b]pyridine
- chelating agent
- antiparasitic agent
Component of
References
- ↑ 1.0 1.1 Rizk et al. J Pharmaceutical & Biomedical Analysis 27:813-20, 2002
- ↑ Melov S. '...and C is for Clioquinol' - the AbetaCs of Alzheimer's disease. Trends Neurosci. 2002 Mar;25(3):121-3; discussion 123-4. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/11852134
- ↑ Wang Y et al The anti-neurodegeneration drug clioquinol inhibits the aging- associated protein CLK-1. J Biol Chem. 2009 Jan 2;284(1):314-23. Epub 2008 Oct 15. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18927074